E-cadherin (cadh), a member of a family of integral membrane glycoproteins that represent the major component of adherens junctions (AJs), mediates cell-cell adhesion through the calcium-dependent homophilic interaction of its extracellular domain. Metastatic human carcinomas frequently lose E-cadh expression, whereas epithelial ovarian cancer (EOCs) maintain properties characteristic of Mu¨llerian epithelium during tumor progression, including E-cadh expression. Here, we examined the potential role of cell-cell contacts in EOCs through E-cadh homophilic interactions in PI3K/AKT activation whose altered signaling has been implicated in EOC pathogenesis. We show that E-cadh is predominantly expressed at cell-cell contacts and its functionality is necessary and sufficient for the activation of the PI3K/ AKT pathway. E-cadh knockdown and phosphoinositide-3-kinase (PI3K) inhibition complement each other in impairing cell-cycle progression and proliferation of ovarian carcinoma cells. E-cadh is stably bound to the PI3K complex, and the de novo formation of E-cadh/bcatenin complexes following calcium deprivation and subsequent calcium restoration recruits the PI3K p85 subunit to the site of the cell-cell contacts. The finding that E-cadh-mediated AJ formation contributes to PI3K/AKT activation in EOC cells by a mechanism that appears to be restricted to these cells provides the underpinning for therapeutic strategies that exploit PI3K inhibition to halt EOCs.
Introduction
Cadherins consist a family of integral membrane glycoproteins representing the major components of adherens junctions (AJs). E-cadherin (cadh) is expressed predominantly on the surface of epithelial cells, where it has a major function in epithelial histogenesis, tissue stabilization and differentiating function (Van Roy and Berx, 2008) . E-cadh mediates cell-cell adhesion through the calcium-dependent homophilic interaction of its extracellular domain and anchoring of its cytoplasmic domain to the actin cytoskeleton by catenins (ctn). b-Ctn interacts directly with the E-cadh cytoplasmic tail, whereas a-ctn binds to b-ctn and links the complex to the actin cytoskeleton; p120-ctn binds directly to the juxtamembrane domain of the E-cadh tail but not to a-ctn (Niessen and Gottardi, 2008 ). E-cadh-containing AJs ensure that the cytoplasmic pool of both b-ctn and p120-ctn is maintained at low levels, preventing their translocation to the nucleus and transcriptional activation through b-ctn/TCF-LEF or repression through p120-ctn/KAISO (Conacci-Sorrell et al., 2003; van Hengel and Van Roy, 2007) . E-cadh was initially considered a structural protein; however, recent evidence suggests a role for E-cadh in transducing outside-in signals. In normal keratinocytes, such E-cadh-activated signaling pathway appears to involve the phosphoinositide-3-kinase (PI3K) and its downstream effector, the serine/threonine kinase AKT (Calautti et al., 2005; Xie and Bikle, 2007) .
As the E-cadh cytoplasmic tail has no catalytic activity, signaling molecules must be recruited to the cadh/ctn complex for signaling to occur. However, in confluent cells, E-cadh appeared to inhibit receptor tyrosine kinase (RTK) signaling by immobilizing these enzymes, thereby leading to an alteration of ligandreceptor affinity (Qian et al., 2004; Andl and Rustgi, 2005; . The expression of E-cadh is frequently lost in metastatic human carcinomas such as breast, bladder, lung and pancreatic carcinomas, which instead express other cadherins, especially N-cadh. For this reason, E-cadh has been proposed as a tumor suppressor. Invasive carcinoma cells transfected to express E-cadh showed decreased proliferation (Wong and Gumbiner, 2003) , and the metastatic potential of late stage tumors is suppressed in mice transgenically expressing E-cadh (Herzig et al., 2006) . In malignant tumors, the loss of E-cadh is caused by mutation, epigenetic silencing, endocytosis and by the expression of other cadherins. An emphasis needs to be made on hereditary gastric cancer that is specifically associated with CDH1 germ-line mutations (Carneiro et al., 2008) . Despite this suppressive role, E-cadh exhibits a distinct expression pattern during the development of epithelial ovarian cancer (EOC). EOCs originate from the single-cell layer that covers the ovary (ovarian surface epithelium, OSE), which normally shows both epithelial and mesenchymal characteristics retaining a high degree of plasticity, expressing vimentin together with cytokeratins 8 and 18. Conversely, ovarian inclusion cysts and carcinomas have properties characteristic of Mu¨llerian epithelium, including expression of the specific epithelial marker E-cadh (Sundfeldt, 2003; Reddy et al., 2005; Ahmed et al., 2007) . We demonstrated that the expression and location of E-cadh in EOC cells could be altered by the downregulated expression of caveolin-1, leading to a significant alteration in src kinase activity, and possibly contributing to the spread of EOC cells in the peritoneal cavity (Miotti et al., 2005) .
The molecular pathogenesis and progression of EOC remains poorly understood, although the list of major gene alterations that may directly or indirectly contribute to EOC development and progression is growing (Aunoble et al., 2000) . The epidermal growth factor receptor/HER2/MAPK and PI3K/AKT pathways have been implicated in the pathogenesis of EOCs. Amplification of the PI3KCA gene, which encodes the p110a subunit of PI3K, was found in 25-40% of ovarian cancers (Vivanco and Sawyers, 2002; Zhang et al., 2007) . Mutation of the PI3KCA gene has been found in about 10% of advanced EOCs (Campbell et al., 2004; Levine et al., 2005; Wang et al., 2005) . Alterations of signaling through multiple components of the PI3K/AKT pathway can be considered a hallmark of EOC (Brugge et al., 2007; Woenckhaus et al., 2007) . A previous report established that E-cadh-mediated cell-cell adhesion triggered the activation of PI3K/AKT and MAPK pathways in the ovarian carcinoma cell line OVCAR3 (Reddy et al., 2005) . However, it was not defined whether E-cadh engagement and PI3K/AKT activation are locally coordinated.
Our present analysis aims to determine how E-cadh homophilic interaction contributes to PI3K/AKT activation in EOCs. We observed in two ovarian carcinoma cell lines, SKOV3 and OAW42, that E-cadh is predominantly expressed at cell-cell contacts and its expression and functionality are necessary and sufficient for the induction of PI3K/AKT activation, thus increasing proliferation of ovarian carcinoma cells. Moreover, we find that PI3K/AKT activation occurs when E-cadh/b-ctn complexes are de novo formed and the PI3K-p85 subunit is recruited at the site of cell-cell contacts. The observed contribution of E-cadh in PI3K activation and control of growth that appears to be restricted to EOC cells might provide an avenue to new therapeutic strategies against EOC.
Results
AKT activation and proliferation are downmodulated on E-cadh knockdown or loss of function in ovarian carcinoma cells To examine whether the E-cadh-expressing ovarian carcinoma cell lines SKOV3 and OAW42 could form AJs, the subcellular distribution of E-cadh, a-, b-and p120-ctn was analysed by immunofluorescence analysis (IF) in confluent cells (Figure 1a) . Colocalization of E-cadh with b-ctn in areas of cell-cell contacts was observed in both cell lines, whereas p120-ctn localized at the plasma membrane together with b-ctn and also accumulated in the cell cytoplasm. a-Ctn was also identified predominantly at the cell-cell contacts, and co-staining with fluorescent phalloidin revealed stabilization of actin fibers in the vicinity of the cell membrane, with defined cortical belt of actin cables, confirming the formation of AJs.
E-cadh localization was also evaluated immunohistochemically in sections from benign, low malignant potential (LMP) and malignant ovarian tumors of different histotypes (representative tissue sections shown in Supplementary Figure 1) . Anti-E-cadh stained 39 out of 50 samples (78%); negative samples consisted only carcinomas (Table 1 ). In the E-cadh-expressing tumors, 54% showed staining only at the membrane level, whereas 41% showed staining on the cell membrane and also in the cytoplasm, likely because the majority of these tumors exhibited very high expression of E-cadh (Supplementary Figure 1b) . Accordingly, with other studies (Davies et al., 1998; Marques et al., 2004) , the results indicated that E-cadh was mainly localized at the site of cell-cell contacts in ovarian carcinoma cells.
To evaluate the role of E-cadh expression, SKOV3 and OAW42 ovarian carcinoma cells were treated with a small-interfering RNA (siRNA) against the CDH1 gene or a nonsilencing control siRNA and analysed for AKT phosphorylation and cell growth. After 48 h, E-cadh expression was significantly reduced (by 70-90% in three separate experiments) in both cell lines, concomitant with a decrease in AKT phosphorylation as observed in western blots (Figure 1b, left panel) . Densitometry revealed an 88 and 70% reduction in AKT phosphorylation in SKOV3 and OAW42 cells, respectively ( Figure 1b, right panel) . The reduction in E-cadh expression was accompanied by a decrease in the proliferation rate of Cdh1 siRNA-treated cells with a 30 and a 65% reduction in thymidine incorporation in SKOV3 and OAW42 cells, respectively (Po0.05; Figure 1c ).
AKT phosphorylation was also examined in lysates of SKOV3 and OAW42 cells incubated with the rat anti-E-cadh monoclonal antibody (MAb) DECMA-1 known to inhibit E-cadh homophilic interactions (Figure 1d , left panel). Densitometric analysis revealed a 90 and a 60% decrease in AKT phosphorylation in the DECMA-1-treated SKOV3 and OAW42 cells, respectively, as compared with levels in cells treated with a control rat immunoglobulin G (IgG, right panel). Furthermore, treatment of SKOV3 and OAW42 cells with the PI3K inhibitor Ly294002 led to B90% reduction in AKT phosphorylation in both cell lines (Figure 1e ), indicating that most of the AKT activation depends on PI3K activity.
Together, these results demonstrate that E-cadh homophilic interactions trigger PI3K/AKT phosphorylation in the two ovarian carcinoma cell lines and that most of this activation is E-cadh dependent. Moreover, the proliferation of ovarian carcinoma cells appeared to be related inversely to E-cadh expression.
Calcium-dependent cell-cell contacts trigger PI3K/AKT activation in ovarian carcinoma cells The calcium-dependent homophilic interactions among E-cadh molecules on adjacent cells are critical for the formation and maintenance of AJs in areas of cell-cell contacts (Pece et al., 1999) . To test whether the establishment of intercellular cell-cell interactions might correlate with PI3K/AKT activation, we analysed calcium-dependent AKT phosphorylation in SKOV3 and OAW42 cells grown to confluence in physiological 
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E-cadherin in PI3K/AKT activation in ovary cancer G De Santis et al calcium concentrations followed by EGTA treatment and subsequent incubation in medium containing CaCl 2 (4 mM). As expected, EGTA treatment to deplete calcium-induced cell rounding and a loss of cell-cell adhesion in both cell lines, as monitored by phasecontrast microscopy ( Figure 2a) . A 10-min treatment with calcium at physiological concentrations restored most cell-cell contacts, and after 30 min, all cell-cell contacts appeared to be restored. Western blot analysis of AKT phosphorylation in total cell lysates at various times after EGTA treatment and calcium restoration ( Figure 2b ) showed that EGTA treatment inhibited AKT phosphorylation to undetectable levels, which were progressively restored on calcium restoration, reaching a maximum within 5 min in both SKOV3 and OAW42 cells. Total AKT expression was essentially unaffected on calcium restoration. Densitometric evaluation of AKT phosphorylation showed about 60% reduction with respect to confluent untreated cells on EGTA treatment ( Figure 2c ) in both cell lines, which was completely recovered by 5-min calcium restoration. Note that lysates from both confluent SKOV3 and OAW42 cells showed a basal level of AKT phosphorylation, with calcium restoration inducing a renewal of AKT activation with a 3-and a 3.5-fold increase of AKT phosphorylation in SKOV3 and OAW42 cells, respectively.
These results indicate that calcium-dependent cell-cell adhesion induces PI3K/AKT activation in ovarian carcinoma cells.
AJ formation causes association with PI3K in ovarian carcinoma cells
To determine whether recruitment of the PI3K complex at the site of AJs is required for PI3K/AKT activation, lysates of confluent untreated, EGTA-treated and EGTA/calcium-treated OAW42 cells were immunoprecipitated with anti-E-cadh MAb and analysed by western blotting (Figure 3a) . In untreated cells, E-cadh was associated with the AJs components b-and p120-ctn, as well as with the PI3K-p85 and -p110 subunits. On EGTA treatment, the E-cadh-containing immunocomplex showed the presence of b-ctn and the presence of E-cadherin in PI3K/AKT activation in ovary cancer G De Santis et al p120-ctn, which is known to stabilize E-cadh at AJs , suggesting that some cells maintained some cell-cell contacts. Calcium restoration (10 min) led to a slight increase in the amount of b-and p120-ctn (1.3-fold for both proteins) associated to E-cadh (Figure 3b) . A significant increase (Po0.05) in PI3K-p85 (2.5-fold) associated to E-cadh was detected on calcium restoration, whereas no apparent difference in the amount of co-immununoprecipitated PI3K-p110 was observed (Figure 3b) . Furthermore, the immunoprecipitation (IP) performed with anti-PI3K-p85 revealed an increase in co-immunoprecipitated E-cadh in the lysates on calcium restoration (data not shown).
Confocal microscopy of untreated, EGTA-treated or EGTA/calcium-treated OAW42 cells stained with b-ctn and anti-PI3K-p85 (Figure 3c . Confluent OAW42 cells were left untreated, treated with 4 mM EGTA alone (EGTA) or followed by calcium restoration (EGTA/Ca 2 þ ) for 10 min as described in Materials and methods. (a) Cell lysates were immunoprecipitated with anti-E-cadh monoclonal antibody (MAb) and analysed by western blot with Abs against E-cadh, b-and p120-ctn, and PI3K-p85 and -p110 subunits. b-Actin was used for normalization of gel loading. Results are from one of the three representative experiments performed. Note that E-cadh bound to either high-or lowmolecular-weight isoforms of p120-ctn, inconsistent with studies reporting differential ability of E-and N-cadh to bind p120-ctn (Seidel et al., 2004) . E-cadherin in PI3K/AKT activation in ovary cancer G De Santis et al confluent untreated OAW42 cells, whereas association of E-cadh with PI3K-p85 was detected in highly compacted cell groups but not on flatly spread cells. EGTA treatment dissociated AJs, but colocalization of E-cadh with b-cat was still evident at the cell perimeter of rounded cells, although less apparent at cell-cell contacts, and the E-cadh/PI3K-p85 association was still evident at the cell periphery but not at the adjacent cell E-cadherin in PI3K/AKT activation in ovary cancer G De Santis et al border. On calcium restoration, E-cadh and b-ctn colocalized at the cell-cell contacts, whereas E-cadh and PI3K-p85 colocalization was observed only in cells presenting cell-cell contacts and not in flatly spread cells, suggesting that recruitment of the PI3K is a very rapid phenomenon that occurs soon after the formation of cell-cell contacts. These results are consistent with the notion that an E-cadh/PI3K/p85 complex exists and that calciuminduced E-cadh homophilic interactions allow the recruitment of the PI3K-p85 regulatory subunit to the membrane at sites of the cell-cell contacts, leading to activation of the PI3K-p110 catalytic subunit.
PI3K is not recruited at AJ sites in cells of other oncotypes
To determine whether PI3K recruitment is a general feature of E-cadh-expressing tumor cells, we analysed AKT phosphorylation in EGTA-treated and EGTA/ calcium-treated SW480 colon carcinoma and in MCF-7 breast carcinoma cells known to express E-cadh. Lysates were prepared from untreated confluent cells or from cells treated with EGTA or with EGTA and calcium up to 1 h. Unlike ovarian carcinoma cells, confluent SW480 cells as well as EGTA-treated cells did not show a basal AKT phosphorylation (Figure 4a, left panel) . Calcium restoration led to a slow increase in AKT phosphorylation, reaching a maximum after 30 min and remaining at the same level at 1 h. Confluent MCF-7 cells showed a faint AKT phosphorylated band and a 5-min calcium treatment led to increased band intensity, decreasing thereafter to the basal level (Figure 4a, right panel) .
Lysates of confluent untreated, EGTA-treated and EGTA/calcium-treated SW480 (30 min calcium restoration) and MCF-7 (5 min calcium restoration) cells were immunoprecipitated with anti-E-cadh MAb followed by western blot analysis (Figure 4b) . In untreated and EGTA-treated SW480 cells, E-cadh complex showed the presence of both b-and p120-ctn; in EGTA/calciumtreated cells, the amount of b-ctn was significantly lower than that observed in lysates from EGTA-treated cells. Unlike the observation in ovarian carcinoma cells, E-cadh complexes from SW480 cells showed poor association with PI3K-p85 and none with the p110 subunit. Superimposable results were obtained on IP of MCF-7 lysates using the anti-E-cadh. Note that in both these cell lines, the total amount of expressed PI3K-p110 subunit was very low as compared to that observed in ovarian carcinoma cells.
Epifluorescence analysis of SW480 and MCF-7 cells was carried out to further examine the distribution of E-cadh and b-ctn on EGTA and EGTA/calcium treatments (Figure 4c ). Both untreated cell lines showed E-cadh and b-ctn staining at cell-cell junctions. SW480 cells were rounded and separated on EGTA treatment; after a 30-min calcium treatment, E-cadh staining was localized mainly at the cell membrane, whereas b-ctn showed a strong diffuse staining. In MCF-7 cells, anti-E-cadh and -b-ctn stained the cell membrane, although in a discontinuous manner on EGTA treatment, whereas on EGTA/calcium treatment anti-E-cadh and -b-ctn stains formed AJs. Overall, these results were consistent with those obtained by IP, and demonstrated that E-cadh and PI3K have no physical or functional association at the sites of AJs in nonovarian carcinoma cells.
E-cadh knockdown and PI3K inhibition impair cell-cycle progression of ovarian carcinoma cells On the basis of our experiments demonstrating that AJ formation through E-cadh homophilic ligation is required for PI3K activation, we asked whether knockdown of E-cadh has an additive effect in downregulating the growth of ovarian carcinoma cells in the presence of a PI3K inhibitor. Thus, OAW42 cells were left untreated or treated with a control siRNA or CDH1 siRNA in the absence or presence of increasing concentration of the PI3K-p110 inhibitor Ly294002 (Figure 5a ). Increasing Ly294002 concentrations (from 5 to 40 mM) progressively reduced cell number in the same manner in both untreated and control siRNA-treated cells. The number of cells treated with CDH1 siRNA was significantly lower than the number of cells treated only with control siRNA, confirming that knockdown of E-cadh negatively altered cell growth as shown in Figure 1b . Increasing Ly294002 concentrations (from 5 to 40 mM) also progressively reduced cell number in CDH1 siRNA-treated cells. The effect of Ly294002 was obtained at 50% lower concentration with respect to control siRNA-treated cells.
A cell-cycle analysis of OAW42 cells treated with CDH1 siRNA alone or with Ly294002 alone revealed impairment of G 1 -S transition with a consequent block in G 0 /G 1 and decrease of the S phase (Figure 5b) . Interestingly, E-cadh knockdown together with Ly294002 treatment showed an additive effect in inhibiting cell-cycle progression. In these cells, no induction of apoptosis was observed on E-cadh knockdown and Ly294002 treatment, as evaluated on the basis of the hypodiploid peak or mitochondrial potential (data not shown).
These findings suggest that E-cadh knockdown complements PI3K inhibition in impairing cell-cycle progression and proliferation of ovarian carcinoma cells.
Discussion
In this study, we reported that E-cadh contributes to the activation of the PI3K/AKT pathway and therefore regulates the growth of ovarian carcinoma cells. We find that calcium-dependent E-cadh homophilic interactions trigger PI3K/AKT activation. When such interactions are disrupted by EGTA, the PI3K-p85 regulatory subunit is localized mainly in the cell cytoplasm, whereas reassembly of AJs on calcium restoration is soon followed by recruitment of the PI3K-p85 to the cell membrane bound to the E-cadh complex. More importantly, our evidence indicates that this E-cadh-dependent mechanism of PI3K/AKT activation (a) Confluent SW480 and MCF-7 cells were treated with EGTA alone or followed by Ca 2 þ up to 60 min, allowing the formation of cell-cell contacts. Western blot analysis was performed on total cell lysates with Abs against phosphorylated AKT or AKT. b-Actin was used for normalization of gel loading. Results are from one of the three representative experiments performed. (b) Confluent SW480 and MCF-7 cells were left untreated, treated with 4 mM EGTA alone (EGTA) or followed by calcium restoration (EGTA/Ca 2 þ ) for 30 and 5 min, respectively, as described in Materials and methods. Cell lysates were immunoprecipitated with anti-E-cadh monoclonal antibody (MAb) and analysed by western blot with Abs against E-cadh, b-and p120-ctn, and PI3K-p85 and -p110 subunits. b-Actin was used for normalization of gel loading. Results are from a representative experiment of three experiments performed. (c) Epifluorescence with Abs against E-cadh (green) and b-ctn (red) on confluent SW480 and MCF-7 cells left untreated, treated with 4 mM EGTA alone (EGTA) or followed by calcium restoration (EGTA/Ca 2 þ ) for 30 and 5 min, respectively.
E-cadherin in PI3K/AKT activation in ovary cancer G De Santis et al is present in ovarian carcinoma cells but not in cells from colon or breast carcinomas. Our IP and confocal IF analysis using anti-E-cadh MAb showed that E-cadh in EGTA-disrupted AJs contained some PI3K complex, but in an inactive form, as demonstrated by low AKT phosphorylation. De novo cell-cell contact formation recruited the PI3K-p85 regulatory subunit to activate the PI3K cascade. Indeed, PI3K-p110 catalytic subunit is activated not only when it is in close proximity to its lipid substrates but also when p85 (associated to a stimulated membrane receptor) relieves an inhibitory effect, presumably owing to conformational changes in the p85/p110 complex (Vivanco and Sawyers, 2002) . Because E-cadh has no catalytic domain, we hypothesize that PI3K activation in ovarian carcinoma cells requires stimuli from adjacent cells to allow ligand and receptor contacts, analogous to what is needed for other ligand and receptor pairs such as ephrin-ephrin receptor-mediated signaling (Himanen et al., 2007) . E-cadh homophilic ligation was earlier shown to recruit PI3K complex to the cell membrane through the p85 adapter subunit (Kovacs et al., 2002) . Such E-cadhactivated PI3K cascade has a clear impact on cadh function, as it is required for adhesive strengthening and for the efficient assembly of cadh-based adhesive contacts. More recently, there is evidence that upstream signaling from RTKs and src family kinases upregulates adhesive cadherin function (Pang et al., 2005; .
We find that PI3K recruitment at E-cadh-mediated cell-cell contacts positively regulates PI3K/AKT signaling, thus increasing growth of ovarian carcinoma cells. Indeed, E-cadh knockdown sufficed to impair cell-cycle progression, leading to the same effect exerted by the PI3K inhibitor Ly294002 and confirming the strong dependence of PI3K activation on E-cadh functionality. On cell-cell contact formation, E-cadh has been proposed as a 'relationship molecule' between extra and intracellular environments leading to PI3K/AKT activation in normal cells (Pece et al., 1999; Woodfield et al., 2001 ). E-cadh-mediated cell-cell contacts induce both associations with the PI3K complex and the phospholipase C-g activation in keratinocytes, thus leading to keratinocyte differentiation (Xie and Bikle, 2007) . By contrast, in tumor cells, E-cadh expression is lost and E-cadh ectopic expression inhibits invasiveness and growth in a cell-cell adhesion-independent manner (Wong and Gumbiner, 2003) .
Ovarian carcinomas clearly diverge from the scenario typical of invasive carcinomas. In accord with previous results (Sundfeldt, 2003; Reddy et al., 2005; Ahmed et al., 2007) , we find that ovarian carcinomas continue to express E-cadh and we defined that E-cadh localization is maintained at cell-cell contacts during tumor progression. Furthermore, we and others have also reported that Wnt signaling is not activated in most EOCs except in the endometrioid histotype (Virnekas et al., 1994; Miotti et al., 2005) . Observations in our laboratory indicate that in SKOV3 ovarian carcinoma cells forced to grow in suspension E-cadh expression have increased, possibly contributing to escape from anoikis (Miotti, S, unpublished data) . These observations and a recent comment by Ahmed et al. (2007) , together with the present data, support the notion that EOC cells require E-cadh for growth, and argue against the previously proposed suppressive role of E-cadh in transformed ovarian cells, which behave more similarly to normal cells, that is, keratinocytes (Xie and Bikle, 2007) and Madison Darby canine kidney cells (Pece et al., 1999) .
The data obtained for the two nonovarian carcinoma cell lines suggest that AKT phosphorylation does not directly depend on calcium-mediated cell-cell contacts and that E-cadh is not associated to the PI3K complex in these cells. It is also possible that invasive tumor cells other than EOC have undergone a complete epithelial-mesenchymal transition and have lost E-cadh expression, hence, other membrane proteins regulate PI3K activation. Furthermore, most colon carcinomas present APC mutation and activation of the Wnt pathway (Anderson et al., 2002) , and in more invasive breast carcinomas PI3K is activated by the Her family RTKs. Proteomic analysis on the composition of the PI3K complex in the presence or absence of E-cadh will help to further understand the mechanisms of PI3K pathway activation.
The PI3K pathway is genetically deregulated in human cancer at several levels (Samuels et al., 2005) . Amplification of genomic regions and the somatic mutations of PIK3CA genes encoding the PI3K-p110 catalytic subunit have been reported and related to the activation of the PI3K pathway (Samuels et al., 2004) . PI3K family members have also been shown to exhibit increased gene copy numbers in ovarian cancer (Zhang et al., 2007) , although PI3K-p110 was not systematically analysed in the report. We observe higher expression of PI3K-p110 protein in OAW42 and SKOV3 ovarian carcinoma cells, in which E-cadh was associated with the PI3K complex, as compared to the levels in SW480 and MCF-7 nonovarian carcinoma cells (data not shown). On the other hand, in diverse types of cancers, including breast, colon, liver and ovary, PIK3CA somatic mutations have been found that are gain of function in the PI3K-p110 activation (for review see Vogt et al., 2007) . By searching the Cosmic database (http://www.sanger. ac.uk/genetics/CGP/cosmic/), we found that SW480 cells are wild type for PIK3CA, MCF-7 cells have a mutation within exon 9 (Glu545Lys), whereas both SKOV3 and OAW42 cells have a mutation within exon 20 (His1047Arg and His1047Leu for SKOV3 and OAW42 cells, respectively). These mutations induce conformational changes that modify p110-p85 association (position 545) or access to the substrates (position 1047) increasing p110 activity (Vivanco and Sawyers, 2002; Amzel et al., 2008) . We might hypothesize that PI3K association to the E-cadh complex at AJs of ovarian carcinoma cells might further facilitate substrate access and enzyme activation.
The importance of the PI3K/AKT pathway in various human cancers has been firmly established and efforts have been made to develop drugs targeting components of this pathway. The pivotal role of E-cadh in modulating PI3K/AKT pathway demonstrated here might have important implications for drug design and for the development of new therapeutic strategies against EOC progression.
Materials and methods

Cell lines
Human cell lines, SKOV3 and SW480, and MCF7 cells from ovary, colon and breast carcinomas (all from ATCC), were maintained in RPMI 1640 medium (Sigma, St Louis, MO, USA) supplemented with 10% fetal calf serum (Hyclone, Logan, UT, USA) and 2 mmol/l glutamine. OAW42 human ovarian carcinoma cells (kindly provided by Dr A Ullrich, Max Planck Institute of Biochemistry, Martinsried, Germany) were cultured in MEM with the same supplements.
Antibodies and reagents
Primary rabbit antibodies: anti-b-ctn (C-2206), anti-PI3K-p110 and anti-E-cadh (Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-b-actin, -p120-ctn and anti-E-cadh (rat; clone DECMA-1) for inhibition of cell-cell contacts (Sigma); anti-PI3K-p85 (Cell Signaling Technology, New England BioLabs, Beverly, MA, USA); anti-E-cadh (HECD-1), against E-cadh ectodomain, used for immunoprecipitation (Zymed Laboratories Inc., San Francisco, CA, USA); anti-phospho-Ser 473 AKT (11E6) and total AKT (5C10) (Alexis Biochemicals, Lausen, Switzerland); anti-p120-ctn Ab and anti-E-cadh for immunohistochemistry (BD Transduction Laboratories, Biosciences Pharmingen, Palo Alto, CA, USA); the PI3K inhibitor Ly294002 (Calbiochem, La Jolla, CA, USA); Na 3 VO 4 and propidium iodide (Sigma); protease inhibitory cocktail and octyl-b-glucoside (Boehringer-Mannheim, Germany); Tween 20 (Merck, Hohenbrunn, Germany) and RNase (Roche, Basel, Switzerland); and fluorochrome-conjugated Alexa Fluor 546 phalloidin, Alexa Fluor 488 and Alexa Fluor 546 secondary antibodies (Molecular Probes, Invitrogen, San Francisco, CA, USA).
Immunofluorescence analysis
Immunofluorescence analysis was performed essentially as described (Sanna et al., 2007) . Samples were analysed using an Eclipse TE2000-S microscope with a Â 40 PanFluor objective (Nikon). Images were acquired with ACT-1 software (Nikon) at a resolution of 2250 Â 1800 pixels. Confocal microscopy was carried out using a Microradiance 2000 microscopy (Bio-Rad Laboratories Inc., Hercules, CA, USA) equipped with Ar (488 nm) and HeNe (543 nm) lasers. Images (1024 Â 1024 pixels) were obtained using a Â 60 oil immersion lens and acquired using Lasersharp 2000 software.
Immunohistochemistry
Immunohistochemistry was performed using routine tissue blocks and a commercially available tissue array (A213 ovary cancer, AccuMax Array; Petagen, Korea and CJ1-C ovary cancer; SuperBioChips Laboratories, Korea) essentially as described (Castellano et al., 2006) . For anti-E-cadh, antigen retrieval was carried out as already described (Tomassetti et al., 2008) . Negative or positive staining, on the basis of intensity and percentage of positive cells, was assessed independently by two observers (AT and GDS).
siRNA treatment Cells were transfected with 80 pmol/ml of siRNA duplex against E-cadh mRNA (CDH1) or with scrambled control siRNA (Qiagen-Xeragon, Germantown, MD, USA) essentially as described (Tomassetti et al., 2008) . Cells were harvested 48 h later and protein levels were analysed by western blotting. Cell growth was subsequently monitored by incorporation of radiolabeled thymidine.
Western blotting and immunoprecipitation
Total cell lysates and western blotting were performed essentially as described (Tomassetti et al., 2008) . Blots were viewed and analysed using ChemiDoc XRS and the Quantity One software (Bio-Rad).
Immunoprecipitation was performed as already described (Miotti et al., 2005) . Immunoprecipitated proteins were separated on 4-12% SDS-polyacrylamide gel electrophoresis under reducing conditions.
Cell growth analysis
Cells plated in 96-well plates at a density of 1 Â 10 4 cells per well were transiently transfected with siRNA as described above. DNA synthesis was analysed on the basis of incorporation of [methyl-3 H]thymidine (Amersham Bioscience-GE Healthcare (Piscataway, NJ, USA); 25 Ci/mmol) (1 mCi per well) for 24h as already described (Tomassetti et al., 2008) .
Calcium depletion or restoration and anti-E-cadh Ab (DECMA-1) treatment At 48 h after cell seeding, calcium was removed by incubation of cells at 37 1C with a phosphate-buffered saline (PBS) solution containing 4 mM EGTA. After 10 (SKOV3) or 30 min (OAW42), a medium containing 4 mM calcium was added for the indicated time. In selected experiments, anti-E-cadh MAb (clone DECMA-1) or nonspecific rat IgG (Chemicon, Millipore, Billerica, MA, USA) was added to the calcium-containing medium. In additional studies, the PI3K inhibitor Ly294002 (20 mM) or the appropriate vehicle was added to the medium. Cells were lysed and analysed by western blotting.
Cell-cycle analysis Cells transiently transfected with siRNA as above were incubated with the PI3K inhibitor Ly294002 (20 mM) or the appropriate vehicle was added to the medium. After 48 h, cells were washed twice with PBS and resuspended in cold fixation buffer (5 mM glucose, 137 mM NaCl, 5 mM KCl, 1 mM Na 2 HPO 4 , 1 mM K 2 HPO 4 , 0.7 mM EDTA) and permeabilized with 70% ethanol for 30 min on ice. After two washes with PBS, cells were incubated in PBS containing 100 mg/ml RNase and 50 mg/ml propidium iodide for 30 min at 37 1C. Analysis was carried out using FACSCalibur (Becton Dickinson, San Jose, CA, USA) and data analysis was carried out using MODFit software.
Statistical analyses
GraphPad Prism software (GraphPad Software, San Diego, CA, USA) was used to analyse all data. Significance of differences was determined by Student's t-test.
